Frederick W. Driscoll
Independent DirectorMr. Frederick W. Driscoll, also known as Fred, is Independent Board Member of Adipo Therapeutics, LLC from February 2026. He was Independent Director of Cue Biopharma, Inc. from June 26, 2018 to June 5, 2025. He serves as an Independent Non-Executive Director of Lite Strategy, Inc. (formerly known as MEI Pharma, Inc.) since February 2018 and serves as its Chairperson from July 22, 2024. Mr. Driscoll served as Director at Calliditas Therapeutics AB (publ) since May 30, 2023 until September 30, 2024. He serves as Director of Neosoma Inc. since March 2023. He served as Interim Chief Financial Officer at Invivyd, Inc. from September 2022 to May 2023 and served as its Principal Financial Officer & Principal Accounting Officer since October 13, 2022. He serves as Director at SmartPharm Therapeutics, Inc. He was Chief Financial Officer at Renovacor, Inc. since March 2022 until June 17, 2022 and served as its Corporate Secretary until June 17 2022. He joined Renovacor with executive experience in the biotech industry. He serves as Principal Accounting Officer at Flexion Therapeutics, Inc. since May 31, 2021 and served as its Chief Financial Officer since May 31, 2021 until November 2021. He was also a Member of the merger and acquisitions team that executed the sale of Flexion to Pacira BioSciences in 2021. Mr. Driscoll serves as Lead Independent Director at NantKwest, Inc. since August 2019. Mr. Driscoll was an Independent Director of Cue Biopharma, Inc. since June 26, 2018 to 2025. He had been Interim Chief Financial Officer and Interim Treasurer at Conformis, Inc. since October 23, 2019. Mr. Driscoll served as an Advisor of Flexion Therapeutics, Inc. (formerly, Flexion Development Partners, Inc.) since March 31, 2017 until May 31, 2021. He served as the Chief Financial Officer of Flexion Therapeutics, Inc. since May 2013 until 2017 and May 2021 to November 2021, when company was acquired by Pacira Pharmaceuticals, Incorporated. Mr. Driscoll served as the Chief Financial Officer, Vice President and Treasurer of Novavax, Inc. from August 2009 to May 17, 2013 and also served as its Principal Accounting Officer from November 2009 to May 17, 2013. Mr. Driscoll served as the Chief Executive Officer and President at Genelabs Technologies, Inc. from September 2008 to 2009 and also served as its Chief Financial Officer from November 2007 to 2008. He also served as Principal Accounting Officer of Genelabs Technologies Inc. and Flexion Therapeutics, Inc. He served as Chief Financial Officer of private company Astraris, Inc. He served as the Chief Executive Officer and President of Mateon Therapeutics, Inc. (alternate Name: OXiGENE, Inc.) from 2000 to June 29, 2006 and also served as its Chief Financial Officer from 2006 to 2007. He served as President of Finance and Operations since 2000. From 1996 to 2000, Mr. Driscoll worked at Collagenesis Corporation, as Senior Vice President of Finance and Operations. From 1974 to April 1996, he served in various senior management positions at Instrumentation Laboratory and lastly held as its Vice President of Finance for the Americas. He has financial management experience with biotechnology and medical device companies. Mr. Driscoll served as the Chairman and Director of Mateon Therapeutics, Inc. (alternate Name: OXiGENE, Inc.) since January 1, 2014 until August 17, 2016. He had been a Director of NantKwest, Inc. since September 18, 2017 until 2021. He has been an Independent Director of Cellectar Biosciences, Inc. since April 2017. He serves as a Director of SmartPharm Therapeutics. He serves as a Director of Neurofibromatosis, Inc. Mr. Driscoll served as a Member of Board of Directors of Abpro Corp. (Abpro Therapeutics) since July 2017 until 2018. He served as Independent Director of ImmunityBio, Inc. from January 1, 2021 through March 29, 2021. He served as a Director of Cynapsus Therapeutics Inc. since May 20, 2016 until October 20, 2016. He also served as a Director of Mateon Therapeutics, Inc., (alternate Name: OXiGENE, Inc.) since 2002. Previously, he served as a Director of Genelabs Technologies Inc. since September 2008 until 2009. He earned a B.S. in accounting and finance from Bentley University.
公司职务
- 公司名称Cellectar Biosciences, Inc.股票代码CLRB职务Independent Director
- 公司名称Lite Strategy, Inc.股票代码LITS职务Independent Chairperson共事同僚
- JJJustin J. FileCEO, CFO, Corporate Secretary & Director
- FWFrederick W. DriscollIndependent Chairperson
- AFAnne FreseChief People Officer
- RDRobert D. MassStrategic Advisor
- NRNicholas R. GloverIndependent Non-Executive Director
- JPJames P. FlynnIndependent Director
- JRJoshua RiezmanIndependent Non-Executive Director
